Abbott Laboratories
ABT · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $11,369 | $11,142 | $10,358 | $10,974 |
| % Growth | 2% | 7.6% | -5.6% | – |
| Cost of Goods Sold | $5,031 | $4,854 | $4,914 | $5,376 |
| Gross Profit | $6,338 | $6,288 | $5,444 | $5,598 |
| % Margin | 55.7% | 56.4% | 52.6% | 51% |
| R&D Expenses | $785 | $732 | $703 | $728 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $3,103 | $3,093 | $3,053 | $2,880 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $420 | $411 | $0 | $0 |
| Operating Expenses | $4,308 | $4,236 | $3,756 | $3,608 |
| Operating Income | $2,030 | $2,052 | $1,688 | $1,990 |
| % Margin | 17.9% | 18.4% | 16.3% | 18.1% |
| Other Income/Exp. Net | $150 | $98 | $90 | $40 |
| Pre-Tax Income | $2,180 | $2,150 | $1,778 | $2,030 |
| Tax Expense | $536 | $371 | $453 | -$7,199 |
| Net Income | $1,644 | $1,779 | $1,325 | $9,229 |
| % Margin | 14.5% | 16% | 12.8% | 84.1% |
| EPS | 0.94 | 1.02 | 0.758 | 5.33 |
| % Growth | -7.8% | 34.5% | -85.8% | – |
| EPS Diluted | 0.94 | 1.01 | 0.758 | 5.27 |
| Weighted Avg Shares Out | 1,749 | 1,740 | 1,747 | 1,732 |
| Weighted Avg Shares Out Dil | 1,749 | 1,751 | 1,747 | 1,746 |
| Supplemental Information | – | – | – | – |
| Interest Income | $77 | $71 | $82 | $91 |
| Interest Expense | $44 | $121 | $134 | $152 |
| Depreciation & Amortization | $791 | $777 | $756 | $807 |
| EBITDA | $3,015 | $3,048 | $2,668 | $2,989 |
| % Margin | 26.5% | 27.4% | 25.8% | 27.2% |